Detalhe da pesquisa
1.
Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics.
Breast Cancer Res Treat
; 191(2): 303-317, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34708303
2.
gPKPDSim: a SimBiology®-based GUI application for PKPD modeling in drug development.
J Pharmacokinet Pharmacodyn
; 45(2): 259-275, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29302838
3.
Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics.
J Biol Chem
; 290(50): 29732-41, 2015 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26491012
4.
PBPK-PD modeling for the preclinical development and clinical translation of tau antibodies for Alzheimer's disease.
Front Pharmacol
; 13: 867457, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36120380
5.
Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease.
Sci Transl Med
; 13(593)2021 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33980574
6.
Complex formation of anti-VEGF-C with VEGF-C released during blood coagulation resulted in an artifact in its serum pharmacokinetics.
Pharmacol Res Perspect
; 8(2): e00573, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32125783
7.
Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.
Br J Pharmacol
; 176(19): 3805-3818, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31270798